InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.14
(
0.23%
)
Bitcoin
62,863.65
(
-0.29%
)
Post# of 110
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

johnsyn

Send PM Follow Ignore
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

johnsyn

Re: None

Monday, 06/04/2012 2:14:37 PM

Monday, June 04, 2012 2:14:37 PM

Post# of 110
10:17 AM ASCO oncology conference: Medivation (MDVN -0.6%) and partner Astellas (ALPMY.PK) say their enzalutamide drug for advanced prostate cancer met secondary endpoints in a Phase 3 study. Medivation last month said it has applied for FDA approval to use enzalutamide in men with advanced prostate cancer who had undergone chemo. (see Zytiga)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Start posting your company's news
Only $200 per official company press release!